Resverlogix and Hepalink Start Taiwan/China Trial of CVD/Diabetes Treatment
July 10, 2017 at 04:10 AM EDT
Canada's Resverlogix has begun a Phase III trial in Taiwan of its lead drug, apabetalone, in high-risk patients with cardiovascular disease and type 2 diabetes. Two years ago, Shenzhen Hepalink, a heparin company, acquired greater China rights to the drug in a $440 million deal. Hepalink will underwrite the costs of the greater China trial, and its start triggers a $1 million payment to Resverlogix. The trial will be expanded to include China. The Taiwan-China arm is part of Resverlogix's global apabetalone trial, which will eventually enroll 2,400 patients. More details.... Stock Symbols: (TSX: RVX) (SHZ: 002399) Share this with colleagues: // //